#South Korea #Seoul #Prestige Biopharma #Tuznue #IDC224

Prestige Biopharma IDC Files Patent for Advanced Antibody Delivery System

Prestige Biopharma IDC, a cutting-edge drug research facility of Prestige Biopharma, has made a significant leap in biotechnology by filing a patent for its revolutionary subcutaneous antibody delivery platform, known as 'IDC224.' This new technology is geared towards enhancing both the convenience of administration and the clinical efficacy of antibody treatments, marking an important step forward in the biopharmaceutical field.

Traditionally, antibody therapies are primarily administered through intravenous (IV) infusions, a process that often demands more than an hour to complete and requires the assistance of healthcare professionals. In contrast, the subcutaneous (SC) method proposed by Prestige Biopharma offers patients a quicker and more user-friendly alternative. This method not only heightens patient convenience but also reduces potential complications associated with repeated vascular access, paving the way for a significant shift in the industry towards SC administration.

However, it is crucial to acknowledge the challenges faced by antibody therapeutics regarding the delivery of high-concentration formulations, where technical hurdles have necessitated advanced engineering solutions for effective SC application. Prestige Biopharma IDC has effectively tackled these issues with the innovative IDC224 technology.

Unique Features of IDC224

The IDC224 platform boasts a distinctive transition mechanism where the drug is administered in a liquid state and subsequently transitions into a gel upon exposure to body temperature. This transformation not only allows for sustained drug release but also prolongs the therapeutic effect while diminishing the frequency of dosing. Additionally, the platform is capable of uniformly loading high-concentration antibodies, significantly enhancing the efficiency of the delivery method. Safety is also a priority, with the use of biocompatible and biodegradable materials giving the platform a competitive advantage.

The project lead overseeing the IDC224 development emphasized the integrated design focused on optimizing administration, delivery efficiency, and patient convenience. In pre-clinical trials involving gastric, ovarian, and breast cancer models, the platform demonstrated enhanced therapeutic effects compared to conventional delivery methods. Moreover, this patent complements the existing composition patent held by Prestige Biopharma IDC, acting as an essential 'use patent' that outlines the enhanced anticancer efficacy attributed to this specific formulation.

Strategic Implications for Tuznue®

A noteworthy consideration is IDC224's potential to repurpose Tuznue®, Prestige Biopharma's trastuzumab biosimilar, which has already received approval in Europe in its current formulation. Leveraging this new technology could significantly strengthen product competitiveness and offer differentiated administration options for both patients and healthcare providers in the future.

A spokesperson from Prestige Biopharma IDC stated, “The IDC224 platform not only aims to enhance the durability of the therapeutic impacts of antibodies but also to simplify the administration process. We envision expanding the application of this innovative technology to a wider array of antibody therapeutics.” 

Overview of Tuznue®

Tuznue® is a biosimilar designed to provide a cost-effective therapeutic solution for patients, offering comparable efficacy and safety profiles to Herceptin® (trastuzumab). It is designed for the treatment of patients with HER2-positive metastatic breast cancer (MBC), early-stage HER2-positive breast cancer (EBC), and HER2-positive metastatic gastric cancer (MGC).

About Prestige Biopharma

Founded in 2015 in Singapore, Prestige Biopharma is a pioneering biopharmaceutical company with a diverse range of products in its pipeline. Its flagship projects include first-in-class antibody drugs and essential biosimilars referencing successful blockbuster medications. A significant breakthrough is their PAUF-based antibody drug, Ulenistamab, which has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA, along with recognition from the European EMA and Korean MFDS. A global Phase 1/2a clinical trial is currently in progress across the U.S., Europe, and Asia, aiming to bring this innovative therapy closer to patients.